These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 3239574)

  • 1. Effect of mazindol on growth hormone levels in patients with Duchenne muscular dystrophy.
    Zatz M; Rapaport D; Vainzof M; Pavanello Rde C; Rocha JM; Betti RT; Otto PA
    Am J Med Genet; 1988 Dec; 31(4):821-33. PubMed ID: 3239574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nocturnal rhythm of growth hormone in Duchenne patients: effect of different doses of mazindol and/or cyproheptadine.
    Zatz M; Rapaport D; Pavanello RC; Rocha JM; Vainzof M; Nicolau W
    Am J Med Genet; 1989 Aug; 33(4):457-67. PubMed ID: 2596504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of mazindol on growth hormone secretion in boys with Duchenne muscular dystrophy.
    Coakley JH; Moorcraft J; Hipkin LJ; Smith CS; Griffiths RD; Edwards RH
    J Neurol Neurosurg Psychiatry; 1988 Dec; 51(12):1551-7. PubMed ID: 3221222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Duchenne muscular dystrophy with growth hormone inhibitors.
    Zatz M; Betti RT; Frota-Pessoa O
    Am J Med Genet; 1986 Jul; 24(3):549-66. PubMed ID: 3524231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized, double-blind trial of mazindol in Duchenne dystrophy.
    Griggs RC; Moxley RT; Mendell JR; Fenichel GM; Brooke MH; Miller PJ; Mandel S; Florence J; Schierbecker J; Kaiser KK
    Muscle Nerve; 1990 Dec; 13(12):1169-73. PubMed ID: 2266990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mazindol and growth hormone inhibition in Duchenne muscular dystrophy.
    Zatz M; Vainzof M; Rapaport D; da Rocha JM; Pavanello Rde C; Betti RT
    Am J Med Genet; 1987 Aug; 27(4):993-5. PubMed ID: 3321999
    [No Abstract]   [Full Text] [Related]  

  • 7. [A therapeutic trial of mazindol versus placebo in Duchenne muscular dystrophy. A one-year follow-up study of 14 children].
    Desnuelle C; Serratrice G; N'guyen VK; Richelme C; Pinsard N
    Arch Fr Pediatr; 1989 Dec; 46(10):759-65. PubMed ID: 2697199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abnormal polyamine metabolism in hereditary muscular dystrophies: effect of human growth hormone.
    Rudman D; Kutner MH; Chawla RK; Goldsmith MA
    J Clin Invest; 1980 Jan; 65(1):95-102. PubMed ID: 7350201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth hormone inhibition causes increased selenium levels in Duchenne muscular dystrophy: a possible new approach to therapy.
    Collipp PJ; Kelemen J; Chen SY; Castro-Magana M; Angulo M; Derenoncourt A
    J Med Genet; 1984 Aug; 21(4):254-6. PubMed ID: 6492089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Height and clinical course of Duchenne muscular dystrophy.
    Coakley JH; Griffiths RD; Edwards RH
    Am J Med Genet; 1989 Apr; 32(4):552-4. PubMed ID: 2774003
    [No Abstract]   [Full Text] [Related]  

  • 11. Mazindol in Duchenne muscular dystrophy.
    Coakley JH; Edwards RH; Moorcraft J; Hipkin LJ; Smith CS
    Lancet; 1988 Jan; 1(8578):184. PubMed ID: 2893022
    [No Abstract]   [Full Text] [Related]  

  • 12. Endocrine studies with mazindol in obese patients.
    Dolecek R
    Pharmatherapeutica; 1980; 2(5):309-16. PubMed ID: 6776543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum levels of vascular endothelial growth factor elevated in patients with muscular dystrophy.
    Saito T; Yamamoto Y; Matsumura T; Fujimura H; Shinno S
    Brain Dev; 2009 Sep; 31(8):612-7. PubMed ID: 18980821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic effects of human growth hormone and of estrogens in boys with Duchenne muscular dystrophy.
    Rudman D; Chyatte SB; Patterson JH; Gerron GG; O'Beirne I; Barlow J; Jordan A; Shavin JS
    J Clin Invest; 1972 May; 51(5):1118-24. PubMed ID: 5057128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Therapy of Duchenne muscular dystrophy with umbilical cord blood stem cell transplantation].
    Zhang C; Feng HY; Huang SL; Fang JP; Xiao LL; Yao XL; Chen C; Ye X; Zeng Y; Lu XL; Wen JM; Zhang WX; Li Z; Feng SW; Xu HG; Huang K; Zhou DH; Chen W; Xie YM; Xi J; Zhang M; Li Y; Liu Y
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2005 Aug; 22(4):399-405. PubMed ID: 16086277
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum myoglobin in muscular dystrophy.
    Kagen LJ; Moussavi S; Miller SL; Tsairis P
    Muscle Nerve; 1980; 3(3):221-6. PubMed ID: 7374673
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nine-year follow-up study of heart rate variability in patients with Duchenne-type progressive muscular dystrophy.
    Yotsukura M; Fujii K; Katayama A; Tomono Y; Ando H; Sakata K; Ishihara T; Ishikawa K
    Am Heart J; 1998 Aug; 136(2):289-96. PubMed ID: 9704692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of mazindol on dystrophic mice and on growth in young rats.
    Coakley JH; Jackson MJ; Wagenmakers AJ; Ensor D; Edwards RH
    Comp Biochem Physiol C Comp Pharmacol Toxicol; 1989; 92(2):385-9. PubMed ID: 2565192
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Duchenne muscular dystrophy. Morphological study of erythrocytes after treatment with L-alpha-lysophosphatidyl-choline in dystrophic patients and in the carrier state.
    Dellantonio R; Capriotti M; Angeleri F; Curatola G; Mazzanti L; Bertoli E; Lenaz G
    Acta Neurol Belg; 1981; 81(4):193-8. PubMed ID: 7293730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased water permeability of erythrocyte membranes in patients with Duchenne muscular dystrophy.
    Serbu AM; Marian A; Popescu O; Pop VI; Borza V; Benga I; Benga G
    Muscle Nerve; 1986; 9(3):243-7. PubMed ID: 3702912
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.